Antibodies
26 November 2007
MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis21 November 2007
Roche Submits Application for FDA Approval of Actemra for the Treatment of Rheumatoid Arthritis21 November 2007
Kyto Biopharma Inc. Confirms Definitive Isolation of the Human Vitamin B12 Receptor (TCblR)20 November 2007
Biogen Idec and Neurimmune Therapeutics Announce Alliance to Develop Treatments for Alzheimer’s Disease20 November 2007
Genmab and Glaxosmithkline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program19 November 2007
Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer19 November 2007
Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas16 November 2007
CHMP Adopts Negative Opinion on Appeal on European Application For natalizumab for the Treatment of Crohn’s Disease16 November 2007
Avastin receives positive opinion in Europe for first-line treatment of patients with advanced kidney cancer16 November 2007
UCB to Appeal European Negative Opinion on CIMZIA(R) for the Treatment of Patients with Crohn’s Disease16 November 2007
Abbott’s HUMIRA(R) Receives Positive Opinion from EMEA for Treatment of Moderate to Severe Plaque Psoriasis14 November 2007
ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia14 November 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer12 November 2007
Major Phase 3 Trial Shows Zevalin(R) Extends Progression-Free Survival in one of the most common types of Lymphoma9 November 2007
Seattle Genetics Initiates Phase IIb Clinical Trial of SGN-33 in Combination with Chemotherapy for Acute Myeloid Leukemia8 November 2007
Dyax Corp. Announces Extension of Antibody Library Collaboration with ImClone Systems8 November 2007
Abbott Research Demonstrates Viability of Combining Antibody Functions to Target Two or More Disease-Causing Processes6 November 2007
Micromet’s BiTE(R) Antibodies Reveal Unique Mode of Action6 November 2007
Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders5 November 2007
Positive Results From Peregrine Pharmaceuticals’ Bavituximab Phase l HCV Trial Presented at AASLD Meeting3 November 2007
ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis I2 November 2007
Seattle Genetics Initiates SGN-40 Clinical Trial in Combination with Revlimid for Multiple Myeloma30 October 2007
Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody29 October 2007
Peptech successfully completes Phase I trial for PN0621News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports